Picture someone who has been on an antidepressant for years, finally steps the dose down, and a few days later feels anxious, low and short-tempered. The natural fear is that the depression is back. A small Swiss study suggests that in many such cases it is not.
The research, published in Psychotherapy and Psychosomatics, was led by Michael P. Hengartner of Kalaidos University of Applied Sciences. It argues that emotional distress shortly after a dose cut is generally a withdrawal reaction, not a relapse.
Why the distinction matters
Withdrawal brings physical signs: dizziness, nausea, muscle cramps and “brain zaps,” sudden electroshock-like sensations in the head. It also brings emotional ones, such as depressed mood, irritability, anxiety and anger outbursts. Those look almost the same as depression or anxiety, so doctors struggle to tell them apart. The choice has consequences. If it is relapse, guidelines generally suggest resuming the drug. If it is withdrawal, a better route is smaller, slower dose steps so the body can adjust.
What the team did
They followed 32 adult primary care patients in Switzerland. All had taken antidepressants for an average of 42 months, were in stable remission and planned to stop. Assessments came before tapering began and again at two, four, six, eight, 16 and 26 weeks, using standard questionnaires for depression, anxiety and withdrawal symptoms.
The pattern was consistent. Each dose reduction brought a spike in depression, anxiety and emotional withdrawal symptoms. When the dose stayed steady, anxiety and emotional withdrawal symptoms eased. That wave shape is typical of withdrawal, while a relapse tends to build gradually and does not rise and fall with week-to-week dose changes.
The researchers then accounted for physical withdrawal symptoms statistically. The link between dose cuts and anxiety weakened substantially. For depression, it disappeared entirely. Small reductions, no more than 25 percent of the minimum therapeutic dose, largely avoided the acute spikes.
“Rapid onset of depressive and anxiety symptoms and abatement within a few weeks after sequential dose reductions and stabilizations reflect the typical wave-like pattern of repeated withdrawal reactions,” Hengartner said. In such cases, he advised reducing more slowly and in smaller steps.
Limits
With only 32 participants, the team could not compare drugs or look at how length of use affects withdrawal. Patients tapered at their own pace, the symptoms were self-reported, and gaps between check-ins grew longer later in the study. “Our findings show a pattern that indicates withdrawal effects, but it is not a definite proof,” Hengartner said. He called for a larger cohort and a randomized tapering trial. Effects also vary widely: some people barely notice withdrawal, others have severe, impairing symptoms.
The encouraging part for patients is that a rough stretch during tapering may mean the pace was too fast, not that the illness has returned. Never change or stop a prescribed dose on your own. Consult your doctor for medical advice.
Sources
- Emotional distress when stopping antidepressants appears to be due to withdrawal, not relapse
- Antidepressant withdrawal: slower and lower tapering of SSRIs
- Study Finds the Majority of Increases in Symptoms During Antidepressant Tapering are Related to Withdrawal, Not Relapse
